Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antidepressant
Biotech
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Neurocrine has nabbed a phase 2 trial win after its oral drug reduced depression severity among adults who haven’t benefited from prior therapies.
Gabrielle Masson
Apr 23, 2024 10:44am
Eliem axes depression drug, lays off 55% of team to stretch cash
Feb 10, 2023 6:00am
Relmada rails against 'implausible' phase 3 depression data
Dec 8, 2022 8:55am
Sage, Biogen post depression data as FDA filing nears completion
Oct 17, 2022 8:01am
Chasing Biogen and Sage, Eliem puts depression drug into phase 2
Oct 5, 2022 10:20am
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in PPD
Jun 1, 2022 8:05am